These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 35157644)

  • 21. Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada.
    Procter TD; Ogasawara H; Spruin S; Wijayasri S; Abraham N; Blaser C; Hutchings K; Shaw A; Ogunnaike-Cooke S
    Vaccine; 2023 Nov; 41(46):6802-6809. PubMed ID: 37806804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies.
    Iheanacho CO; Eze UIH
    Futur J Pharm Sci; 2022; 8(1):20. PubMed ID: 35368622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
    Michalik S; Siegerist F; Palankar R; Franzke K; Schindler M; Reder A; Seifert U; Cammann C; Wesche J; Steil L; Hentschker C; Gesell-Salazar M; Reisinger E; Beer M; Endlich N; Greinacher A; Völker U
    Haematologica; 2022 Apr; 107(4):947-957. PubMed ID: 35045692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presumptive Guillain-Barré Syndrome Associated With Receipt of the Ad26.COV2.2.S COVID-19 Vaccine-Reply.
    Woo EJ; Dimova RB; Mba-Jonas A
    JAMA; 2022 Jan; 327(4):393-394. PubMed ID: 35076672
    [No Abstract]   [Full Text] [Related]  

  • 26. Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy.
    Stefanou MI; Karachaliou E; Chondrogianni M; Moschovos C; Bakola E; Foska A; Melanis K; Andreadou E; Voumvourakis K; Papathanasiou M; Boutati E; Tsivgoulis G
    Neurol Res Pract; 2022 Feb; 4(1):6. PubMed ID: 35130960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US.
    Rodriguez EVC; Bouazza FZ; Dauby N; Mullier F; d'Otreppe S; Jissendi Tchofo P; Bartiaux M; Sirjacques C; Roman A; Hermans C; Cliquennois M
    Infection; 2022 Apr; 50(2):531-536. PubMed ID: 34626338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period-United States, 1 January 2022 to 31 March 2022.
    Kompaniyets L; Wiegand RE; Oyalowo AC; Bull-Otterson L; Egwuogu H; Thompson T; Kahihikolo K; Moore L; Jones-Jack N; El Kalach R; Srinivasan A; Messer A; Pilishvili T; Harris AM; Gundlapalli AV; Link-Gelles R; Boehmer TK
    Clin Infect Dis; 2023 May; 76(10):1753-1760. PubMed ID: 36750643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
    Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
    BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
    Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
    JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination.
    Curcio R; Gandolfo V; Alcidi R; Giacomino L; Campanella T; Casarola G; Rossi R; Chiatti L; D'Abbondanza M; Commissari R; Gresele P; Pucci G; Vaudo G
    Int J Infect Dis; 2022 Mar; 116():154-156. PubMed ID: 34986404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two Case Reports of Chronic Inflammatory Demyelinating Polyneuropathy After COVID-19 Vaccination.
    Kim S; Lee EK; Sohn E
    J Korean Med Sci; 2023 Feb; 38(8):e57. PubMed ID: 36852853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques.
    Solforosi L; Costes LMM; Tolboom JTBM; McMahan K; Anioke T; Hope D; Murdza T; Sciacca M; Bouffard E; Barrett J; Wu C; Hachmann N; Miller J; Yu J; He X; Jacob-Dolan C; Huber SKR; Dekking L; Chamanza R; Choi Y; Boer KF; Barouch DH; Schuitemaker H; Zahn RC; Wegmann F
    Nat Commun; 2023 Apr; 14(1):1944. PubMed ID: 37029141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
    See I; Su JR; Lale A; Woo EJ; Guh AY; Shimabukuro TT; Streiff MB; Rao AK; Wheeler AP; Beavers SF; Durbin AP; Edwards K; Miller E; Harrington TA; Mba-Jonas A; Nair N; Nguyen DT; Talaat KR; Urrutia VC; Walker SC; Creech CB; Clark TA; DeStefano F; Broder KR
    JAMA; 2021 Jun; 325(24):2448-2456. PubMed ID: 33929487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
    Leung C
    Hum Vaccin Immunother; 2021 Sep; 17(9):2957-2958. PubMed ID: 34032555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    Takuva S; Takalani A; Seocharan I; Yende-Zuma N; Reddy T; Engelbrecht I; Faesen M; Khuto K; Whyte C; Bailey V; Trivella V; Peter J; Opie J; Louw V; Rowji P; Jacobson B; Groenewald P; Dorrington RE; Laubscher R; Bradshaw D; Moultrie H; Fairall L; Sanne I; Gail-Bekker L; Gray G; Goga A; Garrett N;
    PLoS Med; 2022 Jun; 19(6):e1004024. PubMed ID: 35727802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
    Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
    Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
    Dari A; Boulton M; Neyens M; Le Gars M; Valenzuela B; Shukarev G; Cárdenas V; Ruiz-Guiñazú J; Sadoff J; Hoetelmans RMW; Ruixo JJP
    Clin Pharmacol Ther; 2023 Feb; 113(2):380-389. PubMed ID: 36377532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.